Company Profile
Phio Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- PHIO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.05 USD (+0.96%)
Close
Last updated: July 27, 2026
13M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, PHIO closed up 0.96% at $1.05. No new same-company headline was identified in the current news window.
Company overview
Business overview
Phio Pharmaceuticals is a biotechnology company focused on immune-oncology and RNA interference-based approaches to cancer. Its story centers on using gene-silencing science to improve tumor treatment.
Geographic Base and Sector Classification
Phio is headquartered in the United States and listed on NASDAQ. It sits in small-cap oncology biotechnology.
Business Model Characteristics
The company depends on preclinical and early clinical validation, capital discipline, and the ability to show that its platform can create a meaningful cancer signal. Investors usually watch translational progress and financing runway.
Position Within the Biotechnology Landscape
Phio occupies a speculative RNAi-oncology niche within biotech. The stock is catalyst-sensitive because the company is still proving whether its platform can matter clinically.
Future catalysts
Phio’s catalysts are its immune-oncology platform and any clinical or partnership update that shows the technology can still produce value. The company remains early and data-dependent.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Phio Pharmaceuticals (PHIO)?
Phio Pharmaceuticals (PHIO) most recently closed at 1.05 USD, a +0.96% move versus the previous session.
What is the market cap of Phio Pharmaceuticals (PHIO)?
Phio Pharmaceuticals currently has a market capitalization of 13M USD on BioPharmSignal.
What does Phio Pharmaceuticals do?
Phio Pharmaceuticals is a biotechnology company focused on immune-oncology and RNA interference-based approaches to cancer. Its story centers on using gene-silencing science to improve tumor treatment.
On which exchange is PHIO stock listed?
Phio Pharmaceuticals (PHIO) is associated with NASDAQ, United States, Biopharma.
What is Phio?
Phio’s catalysts are its immune-oncology platform and any clinical or partnership update that shows the technology can still produce value.
Which conditions is Phio Pharmaceuticals targeting with Phio?
Phio Pharmaceuticals is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Phio Pharmaceuticals describe recent progress with Phio?
Phio’s catalysts are its immune-oncology platform and any clinical or partnership update that shows the technology can still produce value.
What is Pharmaceuticals?
Phio Pharmaceuticals is a biotechnology company focused on immune-oncology and RNA interference-based approaches to cancer.